Home Newsfeeds SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $120

SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $120

SVB Leerink analyst Daina Graybosch maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $112 to $120.

byBenzinga Newsdesk

January 23, 2023

1 minute read

SVB Leerink analyst Daina Graybosch maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $112 to $120.

Mullen Delivers 50 Additional Class 1 EV Cargo Vans To Randy Marion Automotive Group Invoiced At $1,681,750; To Date, Mullen Has Delivered 100 Class 1 Cargo Vans Invoiced For A Total Of $3,363,500

By Benzinga Newsdesk

January 2, 10:25 AM

To date, Mullen has delivered 100 Class 1 cargo vans invoiced for a total of $3,363,500Company on target to deliver a total of 285 Class 1 vehicles by Jan. 8, 2024BREA, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- via IBN –

MULN

Weed Consumption Permitted, NBA Deal Now Allows Players To Invest In Cannabis, Some Have Already Started

By Maureen Meehan

April 3, 5:01 PM

In addition to ditching cannabis testing for NBA players, details from the league's new collective bargaining agreement will give players the ability to invest in NBA and WNBA teams, as well as promote and/or invest in sports betting and cannabis

CWBHF

Daré Bioscience Announces IDE Approval For A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study Of Ovaprene, An Investigational Hormone-Free Monthly Intravaginal Contraceptive

By Benzinga Newsdesk

October 10, 8:10 AM

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application

DARE

HanesBrands Updates Q4 2022 Financial Outlook; Announces Departure Of Chief Financial Officer Michael Dastugue And Refinancing Plans; Scott Lewis To Serve As Interim CFO, Effective March 1, 2023

By Benzinga Newsdesk

January 12, 5:32 PM

Scott Lewis to Serve as Interim CFO, effective March 1, 2023 HanesBrands Inc. (NYSE:HBI), a global leader in iconic apparel brands, today announced that it expects to report fourth-quarter 2022 net sales

HBI

SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $120

Related Posts

Mullen Delivers 50 Additional Class 1 EV Cargo Vans To Randy Marion Automotive Group Invoiced At $1,681,750; To Date, Mullen Has Delivered 100 Class 1 Cargo Vans Invoiced For A Total Of $3,363,500

Weed Consumption Permitted, NBA Deal Now Allows Players To Invest In Cannabis, Some Have Already Started

Daré Bioscience Announces IDE Approval For A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study Of Ovaprene, An Investigational Hormone-Free Monthly Intravaginal Contraceptive

HanesBrands Updates Q4 2022 Financial Outlook; Announces Departure Of Chief Financial Officer Michael Dastugue And Refinancing Plans; Scott Lewis To Serve As Interim CFO, Effective March 1, 2023